<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Valvular heart disease in patients with end-stage kidney disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Valvular heart disease in patients with end-stage kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Valvular heart disease in patients with end-stage kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rochelle Cunningham, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mary Corretti, MD, FACC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Valvular heart disease is common in patients undergoing maintenance dialysis. Abnormalities include valvular and annular thickening and calcification of any of the heart valves but commonly the aortic and mitral valves, with the subsequent development of valvular regurgitation and/or stenosis of the affected valve.</p><p class="headingAnchor" id="H2"><span class="h1">PREDISPOSING FACTORS</span><span class="headingEndMark"> — </span>Many predisposing factors are associated with the development of valvular disease in dialysis patients, perhaps the most significant being the presence of secondary hyperparathyroidism [<a href="#rid1">1-5</a>]. Valvular calcification is also associated with vascular calcification, hypercalcemia, and hyperphosphatemia, all findings that can occur in patients with marked secondary hyperparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a>.)</p><p>Valvular calcification may also be found in patients without secondary hyperparathyroidism, particularly among those with adynamic bone disease, older patients, and those who have undergone dialysis for a longer duration [<a href="#rid6">6,7</a>]. The association with adynamic bone disease may be related to the use of <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> and calcium-containing phosphate binders, with increased calcium deposition [<a href="#rid8">8</a>]. Progressive disease may be attenuated in part by substituting <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">sevelamer</a> for calcium-containing phosphate binders, as shown in a trial of 200 hemodialysis patients followed over a one-year period [<a href="#rid9">9</a>].</p><p>Additional factors that may enhance the development of valvular heart disease in this patient population include the presence of one or more of the following conditions [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperlipidemia</p><p class="bulletIndent1"><span class="glyph">●</span>Left ventricular hypertrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Malnutrition/inflammatory complex</p><p class="bulletIndent1"><span class="glyph">●</span>Uremic milieu</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertrophic cardiomyopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Mitral valve prolapse</p><p class="bulletIndent1"><span class="glyph">●</span>High cardiac output states</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Infective endocarditis (IE)</p><p class="bulletIndent1"><span class="glyph">●</span>Arteriovenous (AV) fistulae</p><p></p><p>The presence of valvular calcification is also a marker of generalized vascular calcification in patients with end-stage kidney (ESKD) disease [<a href="#rid11">11</a>]. Vascular calcification in this patient population is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7222.html" rel="external">"Vascular calcification in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H1702427914"><span class="h1">PATHOGENESIS AND PATHOLOGY</span><span class="headingEndMark"> — </span>Prior to discussing the different clinical valvular abnormalities in patients with end-stage kidney disease (ESKD), it is helpful to first review the pathogenesis and pathology of heart valve or annulus calcification, and of heart valve thickening. These processes underlie much of the valvular heart disease observed in patients with ESKD.</p><p class="headingAnchor" id="H3"><span class="h2">Valvular and annular calcification</span></p><p class="headingAnchor" id="H4"><span class="h3">Mitral annular calcification</span><span class="headingEndMark"> — </span>Mitral annular calcification (MAC) is a chronic, degenerative process, which involves a slow, progressive calcification of the fibrous mitral annulus. MAC with or without degenerative mitral valve leaflet involvement is a significant and common cause of mitral regurgitation and nonrheumatic mitral stenosis [<a href="#rid12">12,13</a>].</p><p>The reported prevalence of MAC is approximately 8 to 15 percent, with significant increases commonly seen with advanced age, multiple cardiovascular risk factors, and chronic kidney disease [<a href="#rid14">14</a>]. MAC occurs in 10 to 50 percent of patients with ESKD [<a href="#rid1">1,7,15,16</a>]. As previously mentioned, it is associated with vascular calcification, hypercalcemia, and hyperphosphatemia.</p><p>MAC occurs earlier in patients with chronic kidney disease than those without kidney dysfunction due in part to the dialysis procedure alone [<a href="#rid1">1</a>]. In one study, MAC was more common in younger (less than 60 years of age) than older dialysis patients [<a href="#rid7">7</a>]. Since older dialysis patients are commonly dialyzed for fewer years because of a marked increase in mortality, MAC appears to occur more frequently in those dialyzed for a longer period of time. (See  <a class="medical medical_review" href="/z/d/html/1847.html" rel="external">"Patient survival and maintenance dialysis"</a>.)</p><p>MAC is recognized echocardiographically as a uniform echodense rigid band, located posterior to the mitral leaflet and anterior to the left ventricular wall [<a href="#rid3">3</a>]. It can extend along the endocardium of the posterior basal wall and engulf and immobilize the posterior leaflet of the mitral valve. (See  <a class="medical medical_review" href="/z/d/html/5334.html" rel="external">"Echocardiographic evaluation of the mitral valve", section on 'Mitral annular calcification'</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Aortic valve calcification</span><span class="headingEndMark"> — </span>Aortic valve calcification (AVC) is found in 25 to 55 percent of hemodialysis patients, occurring 10 to 20 years earlier than in the general population [<a href="#rid2">2,6,7,15-20</a>]. When adjusted for other cardiovascular risk factors, moderate chronic kidney disease is not significantly associated with AVC [<a href="#rid21">21</a>]. Furthermore, it has been shown that the prevalence and severity of AVC and coronary artery calcium (CAC) are increased among patients with atherosclerotic causes of kidney failure and do not vary with the severity of kidney disease [<a href="#rid22">22</a>].</p><p>A study including 1964 participants from the Chronic Renal Insufficiency Cohort Study revealed that decreased kidney function was associated in a dose-dependent manner with increased levels of AVC, independent of traditional risk factors [<a href="#rid23">23</a>].</p><p>AVC is associated with factors similar to those associated with MAC. AVC occurs more frequently in hemodialysis or peritoneal dialysis patients who are older, have received kidney replacement therapy for a longer period of time, and in those with elevated serum parathyroid hormone, calcium, and/or phosphorus levels [<a href="#rid1">1-3,7,15,24-26</a>]. Other factors that promote the development of AVC include increasing age, enhanced mechanical stress on the valve cusps, minor congenital cusp inequalities, hypertension, inflammation, malnutrition, diabetes, and dyslipidemia [<a href="#rid2">2,5,21,27-29</a>].</p><p class="headingAnchor" id="H347385325"><span class="h3">Combined valvular calcification</span><span class="headingEndMark"> — </span>The co-occurrence of mitral valve and AVC has been reported in 15 to 29 percent of patients with ESKD [<a href="#rid26">26,30,31</a>]. In one study that included 243 hemodialysis patients, calcifications were present in either the mitral valve, aortic valve, or mitral annulus in 100 percent of patients [<a href="#rid32">32</a>]. Fewer than 2 percent of dialysis patients had one site that was free of calcification, and more than 50 percent of patients had at least mild calcification. Mild to moderate mitral valve calcification (MVC) and AVC were reported in 98.8 and 94.8 percent of patients, respectively, exceeding previously documented prevalences. Mild MAC was found in 68.7 percent of patients, and moderate to severe MAC was found in 31.3 percent of patients. Other findings in this study included a significantly increased prevalence of moderate to severe AVC in patients aged ≥65 years, males than females, and in White patients as compared with Black patients [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Tricuspid and pulmonic valve calcification</span><span class="headingEndMark"> — </span>The occurrence of calcific deposits in the tricuspid and pulmonic valve annulus is rare.</p><p class="headingAnchor" id="H7"><span class="h2">Valvular thickening</span><span class="headingEndMark"> — </span>Valvular thickening or sclerosis, which most commonly involves the aortic and mitral valves, is a frequent finding in hemodialysis patients. Among such patients, aortic and mitral valve sclerosis occur in 55 to 69 and 40 to 60 percent of individuals, respectively [<a href="#rid2">2,7</a>].</p><p>Although previously thought to be a nonspecific finding without clinical significance, valvular sclerosis is now recognized to be associated with progressive stenosis and increased cardiovascular mortality [<a href="#rid33">33</a>]. Prospective studies have found that valvular sclerosis may progress, usually gradually, but occasionally rapidly, to clinically significant stenosis [<a href="#rid2">2,34</a>]. In a Doppler echocardiographic study of 62 patients on hemodialysis, 34 had thickening of the aortic cusps; among these patients, eight had aortic stenosis, and eight had aortic regurgitation [<a href="#rid2">2</a>]. Twenty-five patients had thickening of the mitral annulus; among these patients, seven had mitral regurgitation, and three had mitral stenosis. (See  <a class="medical medical_review" href="/z/d/html/8123.html" rel="external">"Aortic valve sclerosis and pathogenesis of calcific aortic stenosis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Histology</span><span class="headingEndMark"> — </span>The thickening typically involves the chordae tendineae, valve cusps, and leaflets [<a href="#rid35">35</a>]. On gross examination, the chordae tendineae show irregular thickening and shortening. Histologically, the chordae tendineae appear as "concentric rings of loose connective tissue around a central dense core."</p><p class="headingAnchor" id="H9"><span class="h3">Pathogenesis</span><span class="headingEndMark"> — </span>The pathogenesis of valvular thickening is unclear. However, the presence of abnormal annular tissue, hyperparathyroidism, uremia, and subclinical infection are possible mechanisms [<a href="#rid2">2,36</a>].</p><p class="headingAnchor" id="H10"><span class="h1">GENERAL ISSUES IN VALVULAR DISEASE</span><span class="headingEndMark"> — </span>The principal valvular abnormalities of clinical consequence observed in dialysis patients are regurgitant and stenotic lesions. Infective endocarditis (IE), conduction abnormalities, and thromboembolism may also occur with these defects.</p><p class="headingAnchor" id="H11"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>The clinical features of patients with valvular disease are similar in those with and without kidney failure, but there are certain issues that are unique among dialysis patients. For example, valvular heart disease may be difficult to diagnose clinically via the physical examination because changing volume status makes the clinical assessment of murmurs difficult. Coexisting conditions, such as anemia and hypertension, also frequently exaggerate murmurs. In addition, valvular dysfunction may be associated with complications during hemodialysis [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/1079.html" rel="external">"Auscultation of heart sounds"</a> and  <a class="medical medical_review" href="/z/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1945.html" rel="external">"Intradialytic hypotension in an otherwise stable patient"</a>.)</p><p>Another clinical issue related to volume status involves the presence of a diastolic murmur commonly heard in patients with end-stage kidney disease (ESKD). The exact origin of this murmur remains controversial. Although it was previously attributed to pericardial disease or aortic insufficiency, the murmur is now considered to arise from the pulmonic valve [<a href="#rid38">38-40</a>]. Typically, the murmur is described as a diastolic, decrescendo murmur that is blowing in quality and occurs immediately after the second heart sound. The maximal intensity is at the left sternal border or sometimes at the apex. It is best heard in the supine position, typically disappears after dialysis, and reappears when the patient becomes volume overloaded [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Echocardiography with Doppler flow analysis is an invaluable diagnostic screening tool for the presence of valvular heart disease; it is the modality of choice to detect and assess valvular dysfunction in patients with and without kidney failure. Echocardiography can also evaluate left ventricular function and pericardial disease. However, prior to performing echocardiography, the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend that the dry weight should be optimized [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/5334.html" rel="external">"Echocardiographic evaluation of the mitral valve"</a>.)</p><p>Two-dimensional echocardiography permits a real-time evaluation of the anatomy of the valve, subvalvular structures, annulus, and other cardiac structures. Doppler flow analysis can also evaluate the degree of regurgitation/stenosis and flow dynamics. In patients with known valvular heart disease, serial echocardiograms are recommended to follow the progression of disease.</p><p>Although echocardiography most commonly provides an accurate assessment of disease severity, cardiac catheterization may be necessary in patients with aortic stenosis or regurgitation, settings in which hemodynamic severity can be difficult to assess noninvasively [<a href="#rid42">42</a>] (see  <a class="medical medical_review" href="/z/d/html/8127.html" rel="external">"Hemodynamics of valvular disorders as measured by cardiac catheterization"</a>). Coronary angiography is principally needed to evaluate for coronary artery disease in patients who may undergo valve replacement [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Among dialysis patients, general therapeutic considerations for the treatment of valvular heart disease that are independent of the specific valvular defect should include the prevention and management of secondary hyperparathyroidism, hyperphosphatemia, hypercalcemia, and hypertension. Prevention is particularly important since there are limited data to show that management after onset is effective [<a href="#rid9">9,43</a>]. One trial found that in patients with ESKD and secondary hyperparathyroidism, treatment with the calcimimetic, <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a>, and low-dose vitamin D supplementation slowed the progression of valvular calcification [<a href="#rid44">44,45</a>]. </p><p>Most investigators agree that the uremic milieu in association with other predisposing factors facilitate premature valvular heart disease and calcium deposition. (See  <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/1848.html" rel="external">"Hypertension in patients on dialysis"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Type of valve</span><span class="headingEndMark"> — </span>Both bioprosthetic and mechanical valves, particularly in the dialysis patient, are at risk for endocarditis. Candidacy for long-term anticoagulation is also a factor in the clinical decision making in selecting a valve as it is required for all mechanical valves. However, accelerated dysfunction is common with bioprosthetic valves, while mechanical valves are associated with long-term function. (See  <a class="medical medical_review" href="/z/d/html/8121.html" rel="external">"Mechanical prosthetic valve thrombosis or obstruction: Clinical manifestations and diagnosis"</a>.)</p><p>The optimal replacement valve (independent of the exact anatomic location) remains somewhat controversial in patients with ESKD. Many authors have traditionally favored a mechanical, not a bioprosthetic, valve. Features that support the use of a mechanical valve are the enhanced risks of accelerated dysfunction and calcification of a bioprosthetic valve due to the uremic milieu.</p><p>Bioprosthetic valves have been used in hemodialysis patients with relatively good short-term results (less than five years). This was illustrated in a retrospective study of nearly 6000 dialysis patients in which survival at two years was similar among those who underwent cardiac valve replacement with a mechanical or bioprosthetic valve (40 percent for both groups) [<a href="#rid46">46</a>].</p><p>Another comparative study of hemodialysis patients in China found equivalent rates of perioperative morbidity and mortality and late survival (47) after cardiac valve replacement with a bioprosthetic versus mechanical valve [<a href="#rid47">47</a>]. Benefits with bioprosthetic valves include a lower incidence of bleeding, thrombosis, and stroke (both early and late events) [<a href="#rid48">48-50</a>]. A meta-analysis that examined the heart valve prosthesis selection in patients with ESKD found no difference in survival between bioprosthetic and mechanical prosthetic valve types [<a href="#rid51">51</a>]. However, as demonstrated in earlier studies, valve replacement with bioprosthesis was associated with fewer valve-related complications compared with mechanical prostheses. A single-center, retrospective study of 202 patients with ESKD undergoing valve replacement over a 12-year period found no difference in 30-day mortality (19.9 percent) between bioprosthetic and mechanical valve replacements [<a href="#rid52">52</a>]. However, 10-year survival was poor at 18 percent and was not influenced by the valve type implanted.</p><p>To improve specific patient survival, decrease morbidity, and reduce symptoms, the type of valve chosen should be individualized, with the decision based upon the age and clinical and functional status of the patient. Mechanical valves, particularly for the mitral valve, should be considered in younger and healthier patients; however, these individuals may be at a higher risk for bleeding and thrombotic complications. Careful consideration should be given in older patients, weighing such variables as the risk for bleeding, stroke, and the presence of hypercalcemia and/or hyperphosphatemia.</p><p>In general, both mechanical and bioprosthetic valves can be used in dialysis patients, as recommended in the 2005 KDOQI guidelines [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H195510507"><span class="h3">Type of procedure</span><span class="headingEndMark"> — </span>Among patients with ESKD, the choice of the procedure for valve replacement needs to be individualized. Due to lack of prospective studies, the risks and benefits of surgical valve replacement compared with transcatheter valve implantation (TAVI) are not well established in this population [<a href="#rid53">53,54</a>]. Given the significantly reduced survival of patients with valvular heart disease and ESKD, the type of procedure is especially important because the median survival of &gt;2 years is considered the threshold for cost-effectiveness of TAVI in the general population [<a href="#rid55">55</a>]. Detailed evaluations regarding choice of procedures in the general population are discussed at length elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8154.html" rel="external">"Indications for valve replacement for high gradient aortic stenosis in adults", section on 'Choice of surgical or transcatheter intervention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83110.html" rel="external">"Choice of intervention for severe calcific aortic stenosis", section on 'TAVI versus SAVR'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8138.html" rel="external">"Surgical procedures for severe chronic mitral regurgitation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8140.html" rel="external">"Surgical and investigational approaches to management of mitral stenosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8136.html" rel="external">"Tricuspid stenosis", section on 'Intervention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/114558.html" rel="external">"Pulmonic stenosis in infants and children: Management and outcome", section on 'Transcatheter procedures'</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Delivery of dialysis</span><span class="headingEndMark"> — </span>Whether the delivery of intensive doses of dialysis prior to or during surgery improves outcomes is unknown. In general, dialysis should at least be provided the day before surgery. (See  <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">"Medical management of the dialysis patient undergoing surgery"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>The survival of dialysis patients requiring valve replacement(s) (with or without coronary artery revascularization) is approximately 36 to 55 percent at five years, which is comparable to dialysis patients without valvular disease [<a href="#rid6">6,50</a>]. Many patients report clinical symptomatic improvement, as well as improvement in New York Heart Association (NYHA) classification [<a href="#rid6">6,50</a>].</p><p>The presence of cardiac valvular calcification has been an important negative prognostic factor in some studies [<a href="#rid56">56-58</a>]. Among nearly 200 peritoneal dialysis patients, valve calcification as detected by echocardiography at baseline was associated with a 2.5- and 5.4-fold increased risk of all-cause and cardiovascular death, respectively, at follow-up at 1.5 years [<a href="#rid59">59</a>]. Almost all patients (90 percent) with both valvular calcification and atherosclerotic vascular disease had died by one year, with death occurring in 21 and 23 percent of those with either abnormality alone and 13 percent of those with neither complication. A study of 144 adult hemodialysis patients found an increase in mortality for patients with valvular calcification of the mitral and aortic valve [<a href="#rid58">58</a>]. However, after adjustments for age, sex, race, diabetes mellitus, history of atherosclerotic disease, and pulse pressure, only mitral valve calcification (MVC) remained independently associated with all-cause mortality. Patients with calcification of both valves had a twofold increased risk of death compared with those without valvular calcification. Coronary and valvular calcification measured on chest computed tomography (CT) was also associated with all-cause mortality.</p><p>By contrast, in an Italian study of hemodialysis patients, the presence of calcifications was not an independent prognostic factor [<a href="#rid60">60</a>]. After adjustment for other cardiovascular risk factors, left ventricular mass index, and additional clinical characteristics, calcification failed to provide further independent predictive power.</p><p class="headingAnchor" id="H17"><span class="h1">VALVULAR STENOSIS</span><span class="headingEndMark"> — </span>Stenosis of the aortic valve is the most common obstructive abnormality among hemodialysis patients, with the next most frequent lesion being mitral stenosis. By comparison, tricuspid and pulmonic stenoses are rare.</p><p class="headingAnchor" id="H18"><span class="h2">Etiology</span><span class="headingEndMark"> — </span>Stenotic heart valves in patients undergoing maintenance dialysis occur most commonly in association with annular calcification, which (as previously mentioned) is frequently due to hyperparathyroidism and elevated serum levels of calcium and phosphorous. Thus, aortic and mitral stenoses are observed in association with aortic valve calcification (AVC) and mitral valve calcification (MVC), respectively [<a href="#rid2">2</a>]. Similar considerations apply to pulmonic and tricuspid stenosis [<a href="#rid61">61</a>].</p><p>Among an increasingly older dialysis population, enhanced age alone is also a contributing factor to the development of aortic stenosis. Furthermore, aortic stenosis resulting from a bicuspid valve or rheumatic fever occurs at an earlier age among dialysis patients than those without kidney failure because of factors associated with the uremic milieu, particularly calcium and phosphorous abnormalities.</p><p class="headingAnchor" id="H19"><span class="h2">Clinical manifestations, evaluation, and treatment</span><span class="headingEndMark"> — </span>Although the clinical manifestations and treatment of aortic, mitral, pulmonary, and tricuspid stenosis are similar in patients with and without kidney failure, certain features are relatively unique among patients undergoing maintenance dialysis.</p><p class="headingAnchor" id="H20"><span class="h3">Aortic stenosis</span><span class="headingEndMark"> — </span>Approximately 15 to 20 percent of dialysis patients have aortic stenosis, with hemodynamically significant stenosis developing in 3 to 9 percent [<a href="#rid6">6,17,20,62</a>]. In one study of hemodialysis patients, the estimated incidence of symptomatic aortic stenosis was 3.3 percent per year [<a href="#rid20">20</a>].</p><p>The degree of aortic stenosis is related to the degree of calcification [<a href="#rid24">24,28</a>], with the rate of decrease in valve area significantly higher among dialysis patients than those without kidney failure (mean decrease of 0.23 versus 0.05 to 0.1 cm<sup>2</sup> per year for uremic and nonuremic patients, respectively) [<a href="#rid17">17,20,62</a>] (see  <a class="medical medical_review" href="/z/d/html/8115.html" rel="external">"Aortic valve area in aortic stenosis in adults"</a>). Aortic stenosis progresses more quickly in end-stage kidney disease (ESKD) patients, with higher metabolic and hemodynamic loads on the aortic valve compared with individuals with normal kidney function [<a href="#rid63">63</a>].</p><p>Patients with aortic stenosis are commonly asymptomatic for a prolonged period of time. Angina, syncope, and dyspnea eventually develop, followed by symptoms and signs of heart failure (see  <a class="medical medical_review" href="/z/d/html/8165.html" rel="external">"Natural history, epidemiology, and prognosis of aortic stenosis"</a>). Progression is significantly more frequent in men than women [<a href="#rid17">17,20,62</a>], with rapid progression to symptomatic aortic stenosis being associated with a significant decrease in survival.</p><p>Among hemodialysis patients with aortic stenosis and left ventricular hypertrophy, aggressive ultrafiltration may lead to episodes of intradialytic hypotension [<a href="#rid6">6</a>]. Excessive reduction of end-diastolic filling pressure may reduce cardiac output and coronary perfusion and result in myocardial ischemia and impaired oxygen delivery [<a href="#rid6">6</a>]. Clinically, this may result in chest pain, dyspnea, syncope, cardiac arrhythmias, and myocardial infarction during dialysis. Thus, the use of controlled ultrafiltration and careful attention to dry weight assessment is essential in the management of these patients.</p><p>The principal sign of aortic stenosis is the characteristic systolic murmur, which is described as a systolic "ejection" murmur. It is typically heard best at the base of the heart where it has a harsh quality. The murmur is transmitted well and equally to the carotid arteries. (See  <a class="medical medical_review" href="/z/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults"</a>.)</p><p>Among dialysis patients, systolic murmurs that are unrelated to aortic stenosis are common, resulting in diagnostic difficulties. Such murmurs include those due to a thickened aortic valve (but without hemodynamic compromise), MVC, and increased blood flow (resulting from hypervolemia) [<a href="#rid64">64</a>].</p><p>The modality of choice in the evaluation of aortic stenosis (as well as all other valvular abnormalities) is echocardiography and Doppler flow analysis. To promote the use of clinically accessible noninvasive imaging, the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend annual Doppler echocardiograms in the following patients [<a href="#rid41">41</a>] (see  <a class="medical medical_review" href="/z/d/html/8164.html" rel="external">"Clinical manifestations and diagnosis of aortic stenosis in adults"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic waitlist patients with aortic valve area ≤1.0 cm<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>Other dialysis patients who are suitable candidates for aortic valve replacement based on overall clinical status</p><p></p><p>Cardiac catheterization may be necessary in some patients [<a href="#rid42">42</a>]. In addition, among patients in whom valve replacement is possible, coronary angiography is required to evaluate for coronary artery disease.</p><p>The timing of valve replacement is similar in patients with or without kidney failure. However, given that even mild disease with noncritical stenosis may result in significant cardiovascular morbidity among dialysis patients, early referral for valve replacement may be indicated. (See  <a class="medical medical_review" href="/z/d/html/8154.html" rel="external">"Indications for valve replacement for high gradient aortic stenosis in adults"</a>.)</p><p>Many authors feel that the replacement valve should be a mechanical rather than a bioprosthetic valve. However, the decision should be made on an individual basis since equivalent results have been noted with the two types of valves [<a href="#rid46">46,49,50</a>]. Complications of the various valves include difficulty in maintaining anticoagulation in patients with a mechanical valve and accelerated valve calcification with a tissue prosthesis.</p><p>Neither the 2020 American College of Cardiology/American Heart Association (ACC/AHA) guidelines nor the older European Society of Cardiology guidelines on the management of valvular heart disease made specific recommendations on the choice of valve in patients with aortic stenosis who have ESKD [<a href="#rid65">65,66</a>]. (See  <a class="medical medical_review" href="/z/d/html/8143.html" rel="external">"Choice of prosthetic heart valve for surgical aortic or mitral valve replacement"</a>.)</p><p class="headingAnchor" id="H21"><span class="h3">Mitral stenosis</span><span class="headingEndMark"> — </span>Among dialysis patients, mitral stenosis is most commonly due to mitral annular calcification (MAC) rather than rheumatic fever [<a href="#rid2">2,67</a>]. Data on prevalence are limited, but a review of 62 hemodialysis patients found mitral stenosis in three patients receiving dialysis [<a href="#rid2">2</a>].</p><p>Mitral stenosis can be associated with a variety of symptoms and signs that are primarily related to the severity of the valvular stenosis as reflected by the cardiac output, pulmonary pressures, and pulmonary vascular resistance (see  <a class="medical medical_review" href="/z/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis"</a>). Hemodialysis may improve clinical symptoms by reducing preload; however, treatment requires careful assessment of dry weight and prevention of excessive ultrafiltration, which can reduce ventricular filling across the stenotic mitral valve. Antibiotic prophylaxis should also be considered in appropriate settings. (See <a class="local">'Infective endocarditis'</a> below.)</p><p>Rate control is important in patients with mitral stenosis who develop atrial tachyarrhythmias since a rapid heart rate can further impair ventricular filling. (See  <a class="medical medical_review" href="/z/d/html/8139.html" rel="external">"Rheumatic mitral stenosis: Overview of management"</a>.)</p><p>Percutaneous mitral balloon valvotomy generally provides relief of symptoms in patients with mitral stenosis if the valve morphology is favorable. However, the use of this technique is generally contraindicated in patients with significant valvular and subvalvular calcification, mitral regurgitation, and left atrial or left atrial appendage clot. In such cases, open commissurotomy, valve reconstruction, or mitral valve replacement is preferable [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/8161.html" rel="external">"Percutaneous mitral balloon commissurotomy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8140.html" rel="external">"Surgical and investigational approaches to management of mitral stenosis"</a>.)</p><p class="headingAnchor" id="H22"><span class="h3">Pulmonic stenosis</span><span class="headingEndMark"> — </span>Calcific pulmonic deposits, when present, are often associated with pulmonic valve stenosis in dialysis patients [<a href="#rid68">68</a>]. This is usually accompanied by increased right ventricular systolic pressure and, eventually, right ventricular hypertrophy [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/8120.html" rel="external">"Clinical manifestations and diagnosis of pulmonic stenosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8118.html" rel="external">"Pulmonic valve stenosis in adults: Management"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">VALVULAR REGURGITATION</span><span class="headingEndMark"> — </span>A high prevalence of mitral, tricuspid, and aortic regurgitation is observed in dialysis patients [<a href="#rid2">2,7</a>]. Mitral regurgitation is most common [<a href="#rid7">7,70</a>]. In a series of 75 patients with a mean age of 59 years, valvular regurgitation of the mitral, tricuspid, and aortic valves occurred in 95, 65, and 38 percent of patients, respectively [<a href="#rid7">7</a>]. Additional findings included:</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate and severe regurgitation of the mitral valve occurred in 27 and 13 percent of patients, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate and severe regurgitation of the tricuspid valve occurred in 13 and 5 percent of patients, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate aortic regurgitation was present in 4 percent of patients, while the incidence of severe aortic regurgitation was not reported.</p><p></p><p>The prevalence and degree of regurgitation varies with volume status, degree of left ventricular function, and medications administered (particularly antihypertensive agents), with changes in volume status being the most significant. One study of 21 hemodialysis patients with both mitral and tricuspid valve regurgitation assessed whether valvular insufficiency disappeared with aggressive ultrafiltration [<a href="#rid71">71</a>]. After intensified sessions resulting in a decrease in body weight of approximately 5.4 kg, mitral and tricuspid regurgitation vanished in 13 and 14 patients, respectively. Among those with persistent abnormalities, the degree of regurgitation was much less severe.</p><p class="headingAnchor" id="H24"><span class="h2">Etiology</span><span class="headingEndMark"> — </span>The disappearance of regurgitant lesions with aggressive volume and blood pressure control suggests that most valvular insufficiency in dialysis patients is "functional" in origin. Valvular calcification appears to be responsible for most other cases, while infective endocarditis (IE) may also result in a regurgitant lesion (see <a class="local">'Infective endocarditis'</a> below). In addition, mitral and aortic regurgitation may be more common in polycystic kidney disease, the former due in part to a possibly enhanced incidence of mitral valve prolapse [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/1679.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Extrarenal manifestations"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Clinical manifestations, evaluation, and treatment</span><span class="headingEndMark"> — </span>The clinical features of regurgitant lesions are described in detail separately (see  <a class="medical medical_review" href="/z/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/111634.html" rel="external">"Clinical manifestations and diagnosis of surgical aortic and mitral prosthetic valve regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/8159.html" rel="external">"Clinical manifestations and diagnosis of chronic aortic regurgitation in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8160.html" rel="external">"Natural history and management of chronic aortic regurgitation in adults"</a>). However, there are issues that are unique to patients with end-stage kidney disease (ESKD). Compared with patients without kidney failure, the management of regurgitant lesions in dialysis patients, particularly mitral and tricuspid regurgitation, should focus upon volume and blood pressure control. Aortic regurgitation is also worsened in the setting of elevated systolic pressure and increased afterload conditions. Aggressive ultrafiltration to attain clinical dry weight and optimal blood pressure control (with antihypertensive medications, if necessary) should be therapeutic goals in these patients. The attainment of optimal intravascular volume may eliminate or severely reduce regurgitant valvular lesions, as well as diminish the clinical murmurs associated with these lesions [<a href="#rid71">71</a>].</p><p>However, more aggressive ultrafiltration does not always improve the clinical status of the patient. This finding may signal more advanced ventricular dysfunction.</p><p class="headingAnchor" id="H26"><span class="h1">INFECTIVE ENDOCARDITIS</span><span class="headingEndMark"> — </span>Infective endocarditis (IE) occurs in approximately 3 percent of patients receiving hemodialysis and approximately 9 percent of those with an infected access [<a href="#rid73">73</a>]. Thus, the presence of a vascular access is a significant risk factor for the development of IE, including a primary arteriovenous (AV) fistula [<a href="#rid74">74-76</a>].</p><p>Most data related to IE in dialysis patients are derived from relatively small studies. The following are the two largest reports describing the clinical features of patients with end-stage kidney disease (ESKD) and IE:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 40 dialysis patients with definite endocarditis, access types were an AV fistula, intravenous catheter, and polytetrafluoroethylene graft in 60, 30, and 18 percent, respectively [<a href="#rid77">77</a>]. The mitral valve, aortic valve, or both were infected in 53, 20, and 20 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series of 28 dialysis patients with 30 episodes of endocarditis, the source of sepsis was related to a tunnel catheter, AV fistula, polytetrafluoroethylene graft, and nontunneled catheter in 48, 32, 12, and 4 percent of patients, respectively [<a href="#rid75">75</a>]. Infection of the mitral valve, aortic valve, or both valves occurred in 41, 38, and 17 percent, respectively. Over one-half of affected patients had an abnormal valve, frequently calcified, prior to the valve infection.</p><p></p><p>IE is also a known complication of mitral annular calcification (MAC). In one report, IE occurred in approximately 4 percent of patients with this abnormality [<a href="#rid78">78</a>].</p><p>The short- and long-term survival of dialysis patients with IE is poor and has not improved over time. In a retrospective United States study of over 13,000 patients, the in-hospital mortality rate for those with IE was 24 percent [<a href="#rid79">79</a>]. In addition, among those hospitalized between 1977 and 1991, between 1992 and 1996, and between 1997 and 2000, the survival rates at one year were 46, 41, and 38 percent, respectively, while the three-year rates were 24, 21, and 18 percent, respectively. Similar poor outcomes were reported in an analysis from the Hemodialysis (HEMO) study [<a href="#rid80">80</a>]. </p><p>A poor prognosis was also seen in patients on dialysis who required valve replacement after treatment for endocarditis, with a one-year mortality of approximately 50 percent [<a href="#rid81">81</a>].</p><p>The clinical manifestations and treatment of IE are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"</a> and  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">ADDITIONAL COMPLICATIONS</span><span class="headingEndMark"> — </span>Dialysis patients with valvular heart abnormalities are at an increased risk of developing conduction disturbances and thromboembolism.</p><p class="headingAnchor" id="H28"><span class="h2">Arrhythmias and conduction abnormalities</span><span class="headingEndMark"> — </span>Several arrhythmias and conduction system abnormalities, such as supraventricular arrhythmias, sinus node dysfunction, atrioventricular (AV) nodal, and intraventricular blocks, are common in patients with mitral annular calcification (MAC) and aortic valve calcification (AVC) with or without stenosis [<a href="#rid43">43,78,82-86</a>]. This may be in part hemodynamically mediated, but calcification within the conduction system is probably more important [<a href="#rid43">43</a>].</p><p>Atrial fibrillation is a particularly common finding [<a href="#rid78">78</a>]. In one study, for example, atrial fibrillation occurred in 29 percent of patients with MAC [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H29"><span class="h2">Thromboembolism</span><span class="headingEndMark"> — </span>Thromboembolism is another significant complication of MAC and AVC, with numerous reports of calcific emboli occurring in those with calcified valves [<a href="#rid78">78,87-89</a>]. As with valvular infection, superimposed thrombus can form on the calcified annulus. The thrombotic or ulcerative changes that occur within heavily calcified valves when exposed to the intracardiac lumen can result in an erupted mass of calcium entering the systemic circulation [<a href="#rid78">78</a>]. Additional factors that contribute to calcific thromboemboli include the presence of cardiac arrhythmias and left atrial enlargement [<a href="#rid78">78</a>].</p><p>Thromboemboli in patients with MAC usually result in cerebral ischemia. By comparison, those with AVC experience relatively more episodes of retinal emboli, resulting in retinal artery occlusion and transient monocular blindness. This difference suggests that emboli in patients with AVC are relatively small in size [<a href="#rid90">90</a>].</p><p>Other potential sources for stroke often coexist with valvular calcification; these include dilated cardiomyopathy with left atrial enlargement, infective endocarditis (IE), intracardiac thrombosis, and cardiac arrhythmias [<a href="#rid78">78,90,91</a>]. Atrial fibrillation, for example, has been found in 50 percent of patients with MAC and cerebral infarction [<a href="#rid90">90</a>]. The treatment of these patients is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predisposing factors</strong> – Valvular heart disease is common in patients undergoing maintenance dialysis. Many predisposing factors are associated with the development of valvular disease in this population. These include secondary hyperparathyroidism, elevated serum levels of calcium and phosphorus, vascular calcification, uremic milieu, and a host of other factors. (See <a class="local">'Predisposing factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Valvular and annular calcification</strong> – Among those with end-stage kidney disease (ESKD), mitral annular and aortic valve calcification (MAC and AVC) occur in 10 to 50 percent and 25 to 55 percent of patients, respectively. By comparison, the occurrence of tricuspid and pulmonic valvular calcification is rare. (See <a class="local">'Valvular and annular calcification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Valvular thickening</strong> – Valvular thickening or sclerosis of the aortic and mitral valve is a frequent occurrence in hemodialysis patients, occurring in 55 to 69 percent of individuals. Valvular sclerosis is associated with progressive stenosis and increased cardiovascular mortality. (See <a class="local">'Valvular thickening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General issues in valvular disease</strong> – The clinical diagnosis of valvular heart disease is difficult by physical exam secondary to the changing volume status of dialysis patients, presence of anemia, and hypertension. Thus, echocardiography with Doppler flow analysis is an invaluable diagnostic screening tool for the presence and extent of valvular heart disease. General therapeutic considerations that are independent of the specific valvular defect should encompass the prevention and management of secondary hyperparathyroidism, hyperphosphatemia, hypercalcemia, and hypertension. (See <a class="local">'General issues in valvular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Valvular stenosis</strong> – Stenosis of the aortic valve is the most common obstructive abnormality among hemodialysis patients, with the next most frequent lesion being mitral stenosis. By comparison, tricuspid and pulmonic stenoses are rare. Although the clinical manifestations and treatment of aortic, mitral, pulmonary, and tricuspid stenosis are similar in patients with and without kidney failure, certain features are relatively unique among patients undergoing maintenance dialysis. (See <a class="local">'Valvular stenosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Valvular regurgitation</strong> – A high prevalence of mitral, tricuspid, and aortic regurgitation is observed in dialysis patients. The disappearance of regurgitant lesions with aggressive volume and blood pressure control suggests that most valvular insufficiency in dialysis patients is "functional" in origin, and aggressive ultrafiltration to attain clinical dry weight and optimal blood pressure control should be therapeutic goals in dialysis patients. (See <a class="local">'Valvular regurgitation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Infective endocarditis (IE), arrhythmias, conduction abnormalities, and thromboembolism are significant issues in dialysis patients with valvular abnormalities. (See <a class="local">'Infective endocarditis'</a> above and <a class="local">'Additional complications'</a> above.)</p><p></p><p class="headingAnchor" id="H690024108"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William L Henrich, MD, MACP, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Forman MB, Virmani R, Robertson RM, Stone WJ. Mitral anular calcification in chronic renal failure. Chest 1984; 85:367.</a></li><li><a class="nounderline abstract_t">Straumann E, Meyer B, Misteli M, et al. Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis. Br Heart J 1992; 67:236.</a></li><li><a class="nounderline abstract_t">Nestico PF, Depace NL, Morganroth J, et al. Mitral annular calcification: clinical, pathophysiology, and echocardiographic review. Am Heart J 1984; 107:989.</a></li><li><a class="nounderline abstract_t">Rubel JR, Milford EL. The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population. Am J Kidney Dis 2003; 41:411.</a></li><li><a class="nounderline abstract_t">Kajbaf S, Veinot JP, Ha A, Zimmerman D. Comparison of surgically removed cardiac valves of patients with ESRD with those of the general population. Am J Kidney Dis 2005; 46:86.</a></li><li><a class="nounderline abstract_t">London GM, Pannier B, Marchais SJ, Guerin AP. Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 2000; 11:778.</a></li><li><a class="nounderline abstract_t">Stinebaugh J, Lavie CJ, Milani RV, et al. Doppler echocardiographic assessment of valvular heart disease in patients requiring hemodialysis for end-stage renal disease. South Med J 1995; 88:65.</a></li><li><a class="nounderline abstract_t">Salusky IB, Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 2002; 17:336.</a></li><li><a class="nounderline abstract_t">Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004; 13:134.</a></li><li><a class="nounderline abstract_t">Floege J. When man turns to stone: extraosseous calcification in uremic patients. Kidney Int 2004; 65:2447.</a></li><li><a class="nounderline abstract_t">Wang AY, Ho SS, Wang M, et al. Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease. Arch Intern Med 2005; 165:327.</a></li><li><a class="nounderline abstract_t">Chehab O, Roberts-Thomson R, Bivona A, et al. Management of Patients With Severe Mitral Annular Calcification: JACC State-of-the-Art Review. J Am Coll Cardiol 2022; 80:722.</a></li><li><a class="nounderline abstract_t">Bonow RO, O'Gara PT, Adams DH, et al. 2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020; 75:2236.</a></li><li><a class="nounderline abstract_t">Abramowitz Y, Jilaihawi H, Chakravarty T, et al. Mitral Annulus Calcification. J Am Coll Cardiol 2015; 66:1934.</a></li><li><a class="nounderline abstract_t">Bryg RJ, Gordon PR, Migdal SD. Doppler-detected tricuspid, mitral or aortic regurgitation in end-stage renal disease. Am J Cardiol 1989; 63:750.</a></li><li><a class="nounderline abstract_t">Varma R, Aronow WS, McClung JA, et al. Prevalence of valve calcium and association of valve calcium with coronary artery disease, atherosclerotic vascular disease, and all-cause mortality in 137 patients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005; 95:742.</a></li><li><a class="nounderline abstract_t">Maher ER, Pazianas M, Curtis JR. Calcific aortic stenosis: a complication of chronic uraemia. Nephron 1987; 47:119.</a></li><li><a class="nounderline abstract_t">Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27:394.</a></li><li><a class="nounderline abstract_t">Baglin A, Hanslik T, Vaillant JN, et al. Severe valvular heart disease in patients on chronic dialysis. A five-year multicenter French survey. Ann Med Interne (Paris) 1997; 148:521.</a></li><li><a class="nounderline abstract_t">Ureña P, Malergue MC, Goldfarb B, et al. Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. Nephrologie 1999; 20:217.</a></li><li><a class="nounderline abstract_t">Ix JH, Shlipak MG, Katz R, et al. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2007; 50:412.</a></li><li><a class="nounderline abstract_t">Piers LH, Touw HR, Gansevoort R, et al. Relation of aortic valve and coronary artery calcium in patients with chronic kidney disease to the stage and etiology of the renal disease. Am J Cardiol 2009; 103:1473.</a></li><li><a class="nounderline abstract_t">Guerraty MA, Chai B, Hsu JY, et al. Relation of aortic valve calcium to chronic kidney disease (from the Chronic Renal Insufficiency Cohort Study). Am J Cardiol 2015; 115:1281.</a></li><li><a class="nounderline abstract_t">Maher ER, Young G, Smyth-Walsh B, et al. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 1987; 2:875.</a></li><li><a class="nounderline abstract_t">Gruppen MP, Groothoff JW, Prins M, et al. Cardiac disease in young adult patients with end-stage renal disease since childhood: a Dutch cohort study. Kidney Int 2003; 63:1058.</a></li><li><a class="nounderline abstract_t">Wang C, Jiang L, Feng S, et al. Risk factor analysis of calcification in aortic and mitral valves in maintenance peritoneal dialysis patients. Kidney Blood Press Res 2013; 37:488.</a></li><li><a class="nounderline abstract_t">Merjanian R, Budoff M, Adler S, et al. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int 2003; 64:263.</a></li><li><a class="nounderline abstract_t">Roberts WC. The structure of the aortic valve in clinically isolated aortic stenosis: an autopsy study of 162 patients over 15 years of age. Circulation 1970; 42:91.</a></li><li><a class="nounderline abstract_t">Wang AY, Woo J, Wang M, et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2001; 12:1927.</a></li><li><a class="nounderline abstract_t">Bellasi A, Reiner M, Pétavy F, et al. Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study. J Heart Valve Dis 2013; 22:391.</a></li><li><a class="nounderline abstract_t">Avila-Díaz M, Mora-Villalpando C, Prado-Uribe Mdel C, et al. De novo development of heart valve calcification in incident peritoneal dialysis patients. Arch Med Res 2013; 44:638.</a></li><li><a class="nounderline abstract_t">Kraus MA, Kalra PA, Hunter J, et al. The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study. Ther Adv Chronic Dis 2015; 6:84.</a></li><li><a class="nounderline abstract_t">Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999; 341:142.</a></li><li><a class="nounderline abstract_t">Cosmi JE, Kort S, Tunick PA, et al. The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. Arch Intern Med 2002; 162:2345.</a></li><li><a class="nounderline abstract_t">D'Cruz I, Panetta F, Cohen H, Glick G. Submitral calcification or sclerosis in elderly patients: M mode and two dimensional echocardiography in "mitral anulus calcification". Am J Cardiol 1979; 44:31.</a></li><li><a class="nounderline abstract_t">Abrahams C, D'Cruz I, Kathpalia S. Abnormalities in the mitral valve apparatus in patients undergoing long-term hemodialysis. Autopsy and echocardiographic correlation. Arch Intern Med 1982; 142:1796.</a></li><li><a class="nounderline abstract_t">Masani NN, Miyawaki N, Maesaka JK. A patient with an uncommon etiology of intradialytic hypotension. Semin Dial 2005; 18:435.</a></li><li><a class="nounderline abstract_t">Barratt LJ, Robinson MA, Whitford JA, Lawrence JR. The diastolic murmur of renal failure. N Engl J Med 1976; 295:121.</a></li><li><a class="nounderline abstract_t">Alexander WD, Polak A. Early diastolic murmurs in end-stage renal failure. Br Heart J 1977; 39:900.</a></li><li><a class="nounderline abstract_t">Péres JE, Smith CA, Meltzer VN. Pulmonic valve insufficiency: a common cause of transient diastolic murmurs in renal failure. Ann Intern Med 1985; 103:497.</a></li><li><a class="nounderline abstract_t">K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.</a></li><li><a class="nounderline abstract_t">Carabello BA, Crawford FA Jr. Valvular heart disease. N Engl J Med 1997; 337:32.</a></li><li><a class="nounderline abstract_t">Raine AE. Acquired aortic stenosis in dialysis patients. Nephron 1994; 68:159.</a></li><li><a class="nounderline abstract_t">Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26:1327.</a></li><li><a class="nounderline abstract_t">Marwick TH, Amann K, Bangalore S, et al. Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 96:836.</a></li><li><a class="nounderline abstract_t">Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation 2002; 105:1336.</a></li><li><a class="nounderline abstract_t">Zhibing Q, Xin C, Ming X, et al. Should bioprostheses be considered the valve of choice for dialysis-dependent patients? J Cardiothorac Surg 2013; 8:42.</a></li><li><a class="nounderline abstract_t">Lamberti JJ, Wainer BH, Fisher KA, et al. Calcific stenosis of the porcine heterograft. Ann Thorac Surg 1979; 28:28.</a></li><li><a class="nounderline abstract_t">Kaplon RJ, Cosgrove DM 3rd, Gillinov AM, et al. Cardiac valve replacement in patients on dialysis: influence of prosthesis on survival. Ann Thorac Surg 2000; 70:438.</a></li><li><a class="nounderline abstract_t">Lucke JC, Samy RN, Atkins BZ, et al. Results of valve replacement with mechanical and biological prostheses in chronic renal dialysis patients. Ann Thorac Surg 1997; 64:129.</a></li><li><a class="nounderline abstract_t">Chan V, Chen L, Mesana L, et al. Heart valve prosthesis selection in patients with end-stage renal disease requiring dialysis: a systematic review and meta-analysis. Heart 2011; 97:2033.</a></li><li><a class="nounderline abstract_t">Thourani VH, Sarin EL, Keeling WB, et al. Long-term survival for patients with preoperative renal failure undergoing bioprosthetic or mechanical valve replacement. Ann Thorac Surg 2011; 91:1127.</a></li><li><a class="nounderline abstract_t">Szerlip M, Zajarias A, Vemalapalli S, et al. Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease. J Am Coll Cardiol 2019; 73:2806.</a></li><li><a class="nounderline abstract_t">Otto CM, Kumbhani DJ, Alexander KP, et al. 2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2017; 69:1313.</a></li><li><a class="nounderline abstract_t">Reynolds MR, Magnuson EA, Wang K, et al. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B). Circulation 2012; 125:1102.</a></li><li><a class="nounderline abstract_t">Sharma R, Pellerin D, Gaze DC, et al. Mitral annular calcification predicts mortality and coronary artery disease in end stage renal disease. Atherosclerosis 2007; 191:348.</a></li><li><a class="nounderline abstract_t">Willens HJ, Chirinos JA, Schob A, et al. The relation between mitral annular calcification and mortality in patients undergoing diagnostic coronary angiography. Echocardiography 2006; 23:717.</a></li><li><a class="nounderline abstract_t">Raggi P, Bellasi A, Gamboa C, et al. All-cause mortality in hemodialysis patients with heart valve calcification. Clin J Am Soc Nephrol 2011; 6:1990.</a></li><li><a class="nounderline abstract_t">Wang AY, Wang M, Woo J, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14:159.</a></li><li><a class="nounderline abstract_t">Panuccio V, Tripepi R, Tripepi G, et al. Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2004; 43:479.</a></li><li><a class="nounderline abstract_t">Roberts WC, Waller BF. Effect of chronic hypercalcemia on the heart. An analysis of 18 necropsy patients. Am J Med 1981; 71:371.</a></li><li><a class="nounderline abstract_t">Castro L, Höfling B, Hässler R, et al. Progression of coronary and valvular heart disease in patients on dialysis. Trans Am Soc Artif Intern Organs 1985; 31:647.</a></li><li><a class="nounderline abstract_t">Kim D, Shim CY, Hong GR, et al. Effect of End-Stage Renal Disease on Rate of Progression of Aortic Stenosis. Am J Cardiol 2016; 117:1972.</a></li><li><a class="nounderline abstract_t">Michel PL. Aortic stenosis in chronic renal failure patients treated by dialysis. Nephrol Dial Transplant 1998; 13 Suppl 4:44.</a></li><li><a class="nounderline abstract_t">Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.</a></li><li><a class="nounderline abstract_t">Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021; 77:e25.</a></li><li><a class="nounderline abstract_t">D'Cruz IA, Madu EC. Progression to calcific mitral stenosis in end-stage renal disease. Am J Kidney Dis 1995; 26:956.</a></li><li><a class="nounderline abstract_t">Roberts WC, Mason DT, Morrow AG, Braunwald E. Calcific pulmonic stenosis. Circulation 1968; 37:973.</a></li><li><a class="nounderline abstract_t">Roberts WC, Perloff JK. Mitral valvular disease. A clinicopathologic survey of the conditions causing the mitral valve to function abnormally. Ann Intern Med 1972; 77:939.</a></li><li><a class="nounderline abstract_t">Lavie CJ, Hebert K, Cassidy M. Prevalence and severity of Doppler-detected valvular regurgitation and estimation of right-sided cardiac pressures in patients with normal two-dimensional echocardiograms. Chest 1993; 103:226.</a></li><li><a class="nounderline abstract_t">Cirit M, Ozkahya M, Cinar CS, et al. Disappearance of mitral and tricuspid regurgitation in haemodialysis patients after ultrafiltration. Nephrol Dial Transplant 1998; 13:389.</a></li><li><a class="nounderline abstract_t">Lumiaho A, Ikäheimo R, Miettinen R, et al. Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1. Am J Kidney Dis 2001; 38:1208.</a></li><li><a class="nounderline abstract_t">De Rossi SS, Glick M. Dental considerations for the patient with renal disease receiving hemodialysis. J Am Dent Assoc 1996; 127:211.</a></li><li><a class="nounderline abstract_t">Robinson DL, Fowler VG, Sexton DJ, et al. Bacterial endocarditis in hemodialysis patients. Am J Kidney Dis 1997; 30:521.</a></li><li><a class="nounderline abstract_t">Doulton T, Sabharwal N, Cairns HS, et al. Infective endocarditis in dialysis patients: new challenges and old. Kidney Int 2003; 64:720.</a></li><li><a class="nounderline abstract_t">Nucifora G, Badano LP, Viale P, et al. Infective endocarditis in chronic haemodialysis patients: an increasing clinical challenge. Eur Heart J 2007; 28:2307.</a></li><li><a class="nounderline abstract_t">Spies C, Madison JR, Schatz IJ. Infective endocarditis in patients with end-stage renal disease: clinical presentation and outcome. Arch Intern Med 2004; 164:71.</a></li><li><a class="nounderline abstract_t">Fulkerson PK, Beaver BM, Auseon JC, Graber HL. Calcification of the mitral annulus: etiology, clinical associations, complications and therapy. Am J Med 1979; 66:967.</a></li><li><a class="nounderline abstract_t">Shroff GR, Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients with bacterial endocarditis in the United States. Am J Kidney Dis 2004; 44:1077.</a></li><li><a class="nounderline abstract_t">Allon M, Radeva M, Bailey J, et al. The spectrum of infection-related morbidity in hospitalized haemodialysis patients. Nephrol Dial Transplant 2005; 20:1180.</a></li><li><a class="nounderline abstract_t">Leither MD, Shroff GR, Ding S, et al. Long-term survival of dialysis patients with bacterial endocarditis undergoing valvular replacement surgery in the United States. Circulation 2013; 128:344.</a></li><li><a class="nounderline abstract_t">Nair CK, Sketch MH, Desai R, et al. High prevalence of symptomatic bradyarrhythmias due to atrioventricular node-fascicular and sinus node-atrial disease in patients with mitral anular calcification. Am Heart J 1982; 103:226.</a></li><li><a class="nounderline abstract_t">Mellino M, Salcedo EE, Lever HM, et al. Echographic-quantified severity of mitral anulus calcification: prognostic correlation to related hemodynamic, valvular, rhythm, and conduction abnormalities. Am Heart J 1982; 103:222.</a></li><li><a class="nounderline abstract_t">Burnside JW, Desanctis RW. Bacterial endocarditis on calcification of the mitral anulus fibrosus. Ann Intern Med 1972; 76:615.</a></li><li><a class="nounderline abstract_t">de Bono DP, Warlow CP. Mitral-annulus calcification and cerebral or retinal ischaemia. Lancet 1979; 2:383.</a></li><li><a class="nounderline abstract_t">Osterberger LE, Goldstein S, Khaja F, Lakier JB. Functional mitral stenosis in patients with massive mitral annular calcification. Circulation 1981; 64:472.</a></li><li><a class="nounderline abstract_t">Pomerance A. Pathological and clinical study of calcification of the mitral valve ring. J Clin Pathol 1970; 23:354.</a></li><li><a class="nounderline abstract_t">Katsamakis G, Lukovits TG, Gorelick PB. Calcific cerebral embolism in systemic calciphylaxis. Neurology 1998; 51:295.</a></li><li><a class="nounderline abstract_t">Li Y, Muench A, McGregor DH, Wiegmann TB. Cerebral, myocardial and cutaneous ischemic necrosis associated with calcific emboli from aortic and mitral valve calcification in a patient with end-stage renal disease. Clin Nephrol 2002; 57:468.</a></li><li><a class="nounderline abstract_t">Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol 1986; 43:71.</a></li><li><a class="nounderline abstract_t">Nishimura M, Hashimoto T, Kobayashi H, et al. The high incidence of left atrial appendage thrombosis in patients on maintenance haemodialysis. Nephrol Dial Transplant 2003; 18:2339.</a></li></ol></div><div id="topicVersionRevision">Topic 1909 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6697794" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mitral anular calcification in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1554541" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6372421" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mitral annular calcification: clinical, pathophysiology, and echocardiographic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12552504" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983961" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of surgically removed cardiac valves of patients with ESRD with those of the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10752538" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Calcification of the aortic valve in the dialyzed patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7817230" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Doppler echocardiographic assessment of valvular heart disease in patients requiring hemodialysis for end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11812902" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cardiovascular calcification in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14765851" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149366" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : When man turns to stone: extraosseous calcification in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15710797" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35953138" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management of Patients With Severe Mitral Annular Calcification: JACC State-of-the-Art Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32068084" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Solution Set Oversight Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26493666" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mitral Annulus Calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2923063" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Doppler-detected tricuspid, mitral or aortic regurgitation in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15757600" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence of valve calcium and association of valve calcium with coronary artery disease, atherosclerotic vascular disease, and all-cause mortality in 137 patients undergoing hemodialysis for chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3696315" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Calcific aortic stenosis: a complication of chronic uraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8604709" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9538397" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Severe valvular heart disease in patients on chronic dialysis. A five-year multicenter French survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10480155" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17720520" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19427449" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Relation of aortic valve and coronary artery calcium in patients with chronic kidney disease to the stage and etiology of the renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25791240" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Relation of aortic valve calcium to chronic kidney disease (from the Chronic Renal Insufficiency Cohort Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2889080" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Aortic and mitral valve calcification in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631088" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cardiac disease in young adult patients with end-stage renal disease since childhood: a Dutch cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24247761" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk factor analysis of calcification in aortic and mitral valves in maintenance peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12787418" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5425599" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The structure of the aortic valve in clinically isolated aortic stenosis: an autopsy study of 162 patients over 15 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11518787" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24151766" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24211754" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : De novo development of heart valve calcification in incident peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25984289" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10403851" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12418948" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/453044" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Submitral calcification or sclerosis in elderly patients: M mode and two dimensional echocardiography in "mitral anulus calcification".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7125766" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Abnormalities in the mitral valve apparatus in patients undergoing long-term hemodialysis. Autopsy and echocardiographic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16191186" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A patient with an uncommon etiology of intradialytic hypotension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1272327" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The diastolic murmur of renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/901686" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Early diastolic murmurs in end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4037556" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pulmonic valve insufficiency: a common cause of transient diastolic murmurs in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806502" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9203430" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7830852" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Acquired aortic stenosis in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148030" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31543156" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11901045" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23497614" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Should bioprostheses be considered the valve of choice for dialysis-dependent patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/454040" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Calcific stenosis of the porcine heterograft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10969659" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cardiac valve replacement in patients on dialysis: influence of prosthesis on survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236348" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Results of valve replacement with mechanical and biological prostheses in chronic renal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21990382" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Heart valve prosthesis selection in patients with end-stage renal disease requiring dialysis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21353200" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term survival for patients with preoperative renal failure undergoing bioprosthetic or mechanical valve replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31171086" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28063810" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : 2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22308299" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16647710" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mitral annular calcification predicts mortality and coronary artery disease in end stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16999688" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The relation between mitral annular calcification and mortality in patients undergoing diagnostic coronary angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700824" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : All-cause mortality in hemodialysis patients with heart valve calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12506148" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981606" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7282728" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effect of chronic hypercalcemia on the heart. An analysis of 18 necropsy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3837525" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Progression of coronary and valvular heart disease in patients on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27138183" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effect of End-Stage Renal Disease on Rate of Progression of Aortic Stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9614665" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Aortic stenosis in chronic renal failure patients treated by dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17259184" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33342586" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503072" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Progression to calcific mitral stenosis in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5653056" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Calcific pulmonic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4566285" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mitral valvular disease. A clinicopathologic survey of the conditions causing the mitral valve to function abnormally.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8417884" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prevalence and severity of Doppler-detected valvular regurgitation and estimation of right-sided cardiac pressures in patients with normal two-dimensional echocardiograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9509451" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Disappearance of mitral and tricuspid regurgitation in haemodialysis patients after ultrafiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11728952" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8682990" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Dental considerations for the patient with renal disease receiving hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9328367" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Bacterial endocarditis in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12846771" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Infective endocarditis in dialysis patients: new challenges and old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17656347" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Infective endocarditis in chronic haemodialysis patients: an increasing clinical challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718325" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Infective endocarditis in patients with end-stage renal disease: clinical presentation and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/156499" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Calcification of the mitral annulus: etiology, clinical associations, complications and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558529" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Long-term survival of dialysis patients with bacterial endocarditis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15769823" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The spectrum of infection-related morbidity in hospitalized haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23785002" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Long-term survival of dialysis patients with bacterial endocarditis undergoing valvular replacement surgery in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7055056" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : High prevalence of symptomatic bradyarrhythmias due to atrioventricular node-fascicular and sinus node-atrial disease in patients with mitral anular calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7055055" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Echographic-quantified severity of mitral anulus calcification: prognostic correlation to related hemodynamic, valvular, rhythm, and conduction abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4565484" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Bacterial endocarditis on calcification of the mitral anulus fibrosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/89448" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Mitral-annulus calcification and cerebral or retinal ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7261279" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Functional mitral stenosis in patients with massive mitral annular calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5430424" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pathological and clinical study of calcification of the mitral valve ring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9674827" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Calcific cerebral embolism in systemic calciphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12078952" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cerebral, myocardial and cutaneous ischemic necrosis associated with calcific emboli from aortic and mitral valve calcification in a patient with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510609" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cardiogenic brain embolism. Cerebral Embolism Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14551363" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The high incidence of left atrial appendage thrombosis in patients on maintenance haemodialysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
